KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Operating Expenses (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Operating Expenses for 8 consecutive years, with $146.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 7.44% year-over-year to $146.2 million, compared with a TTM value of $533.8 million through Dec 2025, up 17.78%, and an annual FY2025 reading of $533.8 million, up 17.78% over the prior year.
  • Operating Expenses was $146.2 million for Q4 2025 at Biocryst Pharmaceuticals, up from $129.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $369.2 million in Q4 2023 and bottomed at $100.6 million in Q2 2024.
  • Average Operating Expenses over 3 years is $150.7 million, with a median of $129.8 million recorded in 2025.
  • The sharpest move saw Operating Expenses tumbled 63.15% in 2024, then surged 32.81% in 2025.
  • Year by year, Operating Expenses stood at $369.2 million in 2023, then crashed by 63.15% to $136.0 million in 2024, then grew by 7.44% to $146.2 million in 2025.
  • Business Quant data shows Operating Expenses for BCRX at $146.2 million in Q4 2025, $129.8 million in Q3 2025, and $133.6 million in Q2 2025.